Clinical trials: Relapsed or Refractory Large B-cell Lymphoma
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
DLBCL
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Patients with CD30 positive DLBCL, primary refractory or in first relapse after R-CHOP or R-CHOP-like therapy will receive brentuximab vedotin in combination with R-DHAP, followed in responsive patients by high dose chemotherapy…
- Trial name
- HOVON 136 NHL (NCT03356054)
- Testing
- R-DHAP, Brentuximab Vedotin
- Where
- Netherlands
- Volunteers
- 37 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in patients with relapsed or refractory B-Cell Non-Hodgkin…
- Trial name
- NCT02134262
- Testing
- Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Jichi Medical University
CLL/SLL, NHL
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
- Conditions
- CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT05665062
- Testing
- SYNCAR-001, STK-009, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Synthekine
Adult Diffuse Large Cell Lymphoma, Recurrent
DPX-Survivac and Checkpoint Inhibitor in DLBCL
This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two…
- Conditions
- Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- SPiReL (NCT03349450)
- Testing
- DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg
- Where
- 6 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Sunnybrook Health Sciences Centre
Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with relapsed/refractory Diffuse Large B-cell Lymphoma…
- Trial name
- NCT02142049
- Testing
- Ibrutinib, DA-EPOCH-R, Lenalidomide
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pharmacyclics LLC.
Brain Tumor, Central Nervous System Tumors
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia
- Trial name
- NCT00066248
- Testing
- cyproheptadine hydrochloride, megestrol acetate
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- University of South Florida
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003885
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Our Lady of Mercy Medical Center
B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00119392
- Testing
- rituximab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Fred Hutchinson Cancer Center
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- CERTAIN (NCT04526834)
- Testing
- CD30.CAR-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tessa Therapeutics
Lymphoma, Large B-Cell, Diffuse
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the combination of brentuximab vedotin (BV) and lenalidomide in the treatment of patients with relapsed or refractory diffuse large B-cell…
- Trial name
- NCT02086604
- Testing
- Brentuximab vedotin, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
This was a Phase 1/2 study performed at two clinical centers in the US and UK. It was a single arm, open label study evaluating VSLI plus rituximab in adults with aggressive relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT01851551
- Testing
- Vincristine Sulfate Liposome Injection plus rituximab
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Acrotech Biopharma Inc.
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00006473
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Lymphoma, B-Cell
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.
- Conditions
- Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell
- Trial name
- NCT03682796
- Testing
- TRPH-222
- Where
- 7 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Triphase Research and Development III Corp.
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia.
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Trial name
- NCT04502394
- Testing
- KRT-232, acalabrutinib
- Where
- 45 sites in United States, Australia and 9 more
- Volunteers
- 84 people
- Sponsor
- Kartos Therapeutics, Inc.
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies…
- Conditions
- Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT03547115
- Testing
- voruciclib monotherapy, voruciclib and venetoclax
- Where
- 12 sites in United States
- Volunteers
- 84 people
- Sponsor
- MEI Pharma, Inc.
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00073957
- Testing
- rituximab, cytarabine, liposomal cytarabine
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Non-Hodgkin Lymphoma
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma.
- Trial name
- NCT05950165
- Testing
- CHO-H01, CHO-H01 at RP2D, Lenalidomide
- Where
- 9 sites in Taiwan
- Volunteers
- 37 people
- Sponsor
- Cho Pharma Inc.